September 3, 2026

To
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Scrip Code: 543064

To
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Press Release

Please find annexed press release – "Cohance Lifesciences advances its ADC strategy"

We request you to take the above on record.

Thanking you.

Yours faithfully,

For **Cohance Lifesciences Limited**
(formerly, Suven Pharmaceuticals Limited)
SISIRA KUMAR MISHRA
Digitally signed by SISIRA KUMAR MISHRA
Date: 2026.09.03 20:08:09 +05'30'
Sisir K Mishra
Company Secretary & Compliance Officer

Encl: As above.

Cohance

Cohance Lifesciences advances its ADC strategy

Investment of USD 18 million in NJ Bio and Aruka Bio

September 03, 2026: Cohance Lifesciences Limited today announced two proposed transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: an additional investment of USD 13 million in NJ Bio and a controlling investment of USD 5 million in Aruka Bio. Both the transactions will be funded through internal accruals.

The re-organisation establishes distinct priorities: deeper integration of NJ Bio's customer-facing services with Cohance, and focused development of Aruka's proprietary pipeline through potential partnerships.

NJ Bio: planned succession, continued founder engagement

Cohance will increase its common-equity ownership in NJ Bio from 56.0% to 67.3%, acquiring the entire holdings of Ms. Priyashri Nayak, and the Jain Family Irrevocable Trust. Dr. Jain will retain 32.7%.

Dr. Jain will continue to lead NJ Bio while also advancing Aruka's pipeline and partnership initiatives.

NJ Bio will remain focused on customer-facing contract research, development and manufacturing services. Closer integration will combine its payload-linker and bioconjugation expertise with Cohance's manufacturing capabilities to support customers end-to-end CRDMO development through commercial supply. This integration is expected to strengthen business performance across the combined platform over time.

Aruka Bio: control of the platform, development with partners

Aruka Bio, Inc. is a private biotechnology company based in Princeton, New Jersey, focused on developing next-generation antibody-drug conjugates. Its lead program is currently at the preclinical stage.

Cohance

Cohance's USD 5 million equity investment will fund the buyout of other existing shareholders and convertible noteholders along with working capital.

Following completion and Dr. Jain's upfront equity grant, Aruka will be owned 65% directly by Cohance, 25% by NJ Bio and 10% by Dr. Jain. These percentages are before further dilution from Dr. Jain's performance-linked equity award.

Aruka will become Cohance's direct subsidiary. The investment consolidates control of Aruka's proprietary ADC platform, positioning it to pursue co-development, licensing and other collaborations with pharmaceutical and biotechnology partners as its pipeline progresses.

This follows a review of NJ Bio's performance and integration with Cohance since the original investment in December 2024, which identified an opportunity to strengthen commercial alignment between the two businesses as NJ Bio expands its GMP CDMO services and to give dedicated leadership focus to Aruka's novel drug development pipeline.

Completion is expected by the end of September 2026, subject to definitive agreements, applicable approvals and customary closing conditions.

Dr. Naresh Jain, Founder and CEO, NJ Bio, said: *"I will work across both businesses—supporting NJ Bio's growth and an orderly leadership handover, while working together with Cohance in advancing Aruka's pipeline and exploring development partnerships. Thereafter, I will focus full-time on Aruka as CEO, while continuing to support NJ Bio as a strategic advisor."*

Umang Vohra, Executive Chairman and Group CEO, Cohance Lifesciences, said: *"This reorganisation gives each business a clear focus: strengthening NJ Bio's customer offering through closer integration with Cohance and creating the opportunity for Dr Jain to lead Aruka's next phase. This integration is expected to strengthen business performance across the combined platform over time"*

-ENDS-

About Cohance Lifesciences

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. Leveraging a combined platform with state-of-the-art facilities in India and the U.S., Cohance delivers integrated solutions from early development to commercial supply for leading global pharma companies.

For more information, please contact: www.cohance.com

Cyndrella Carvalho, Head - Investor Relations,
Cohance Lifesciences Limited
Tel: 040 2354 3311
Email: cyndrella.carvalho@cohance.com

Gavin Desa / Konpal Pali
CDR India
Tel: +91 98206 37649/ +91 76619 08341
Email: gavin@cdr-india.com; konpal@cdr-india.com